Form 4: Revolution Medicines' General Counsel Sells Shares to Cover Tax Obligations

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,252 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On March 18, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 1,252 shares of the company's common stock.
• The sale was executed at a price of $31.5832 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
• The sale was an automatic sell-to-cover transaction imposed by the terms of the RSU award.
• Following the transaction, Cislini beneficially owns 55,874 shares, including 48,972 RSUs.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence, often related to compensation and tax planning. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on current insider information.

Stakeholder Impact

• The sale of shares by an insider could be perceived negatively by some shareholders, although the pre-planned nature of the sale mitigates this concern.

Key Dates